Verastem
Investment Year
2010
Sector
Geography
North America - East
Website
www.verastem.com

Verastem

Biopharmaceutical company focused on discovering and developing novel drugs that selectively target cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is translating breakthrough discoveries in cancer stem cell research into new medicines for the treatment of major cancers such as breast cancer. In January 2012, Verastem went public (NASDAQ: VSTM).

News